Premium
Value of interleukin‐ 28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin
Author(s) -
Chen MingYao,
Liu ChenHua,
Chen TingChih,
Su TungHung,
Chen PeiJer,
Chen DingShinn,
Kao JiaHorng,
Liu ChunJen
Publication year - 2014
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.12329
Subject(s) - ribavirin , medicine , genotype , gastroenterology , interleukin 28b , pegylated interferon , hepatitis c virus , hepatocellular carcinoma , combination therapy , peginterferon alfa 2a , immunology , virus , biology , gene , biochemistry
Abstract Background and Aim Chronic hepatitis C ( CHC ) infection is a leading cause of cirrhosis and hepatocellular carcinoma worldwide. Pegylated interferon ( PEG‐IFN ) plus ribavirin ( RBV ) combination therapy remains the standard of care for CHC genotype 1 in many A sian countries, and single nucleotide polymorphism or genotype of the interleukin‐ 28B ( IL28B ) gene is associated with the development of sustained virologic response ( SVR ). The predictive value of IL28B genotype for retreatment outcomes of patients with CHC was only partly clarified and deserves further investigation. Methods A total of 75 CHC genotype 1 Taiwanese patients who relapsed after 24‐week PEG‐IFN / RBV combination therapy and received retreatment with a 48‐week PEG‐IFN / RBV therapy were consecutively enrolled since N ovember 2009. The associations among IL28B rs8099917 genotype, virologic kinetics, and treatment outcomes were evaluated. Results Rapid virologic response ( RVR ) at week 4, end‐of‐treatment virologic response ( EOT‐VR ) and SVR was 37%, 73%, and 52%, respectively. Relapse rate was 29%. None of patients had rs8099917 GG genotype. Patients with TT genotype ( n = 54, 72%) had higher rates of RVR (50% vs 5%, P = 0.0002), end‐of‐treatment virologic response (85% vs 43%, P = 0.0001), and SVR (67% vs 14%, P = 0.0001) than those with GT genotype ( n = 21, 28%). Combination of IL28B TT genotype and achieving RVR had 85% positive and 90% negative predictive values of SVR . Conclusions About half of the T aiwanese CHC relapsers to a previous 24‐week combination therapy achieve SVR after retreatment for 48 weeks. IL28B genotype influences on‐treatment viral kinetics and SVR rate in these retreated patients. Baseline IL28B genotype and RVR can serve as early predictors for treatment success.